Final answer:
Genetically engineered bacteria produce human insulin to provide a sustainable and non-allergenic treatment for diabetes, using E. coli to create humulin, thereby making the treatment more accessible.
Step-by-step explanation:
Scientists might genetically engineer bacteria to produce human insulin primarily to treat diabetes, as many people require insulin therapy. The use of recombinant DNA technology allows for the large-scale production of insulin that is chemically identical to human insulin, known as 'humulin'.
This technological advancement provides a sustainable and less allergenic alternative to insulin previously sourced from animals, such as pigs or cows, which could provoke immune reactions in patients. These genetically engineered bacteria, most notably E. coli, become effective 'factories', synthesizing the human insulin protein efficiently and cost-effectively, making diabetes treatment more accessible and reducing the risk of adverse reactions associated with animal-derived insulin.